Data alert

Blunting the atherosclerotic process in patients with coronary artery disease

Statin therapy lowers serum levels of atherogenic lipoproteins and reduces cardiovascular (CV) morbidity and mortality in a wide range of patients in clinical trials.1-7 These major trials were placebo-controlled, and provide limited evidence about differences between individual statins, or about target levels for lipid lowering.

The Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial8 has now compared the effects of two different statin treatments in patients with established coronary artery disease (CAD). This is the first major study to measure the progression of coronary atherosclerosis using intravascular ultrasound (IVUS), a technique that can quantify plaque by visualization of the coronary arterial wall.

References are listed at the end of the Data Alert.


Download 04DA-REVERSAL.ppt (7 slides - 1.3MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5 Slide 6 Slide 7
Data_Alert.pdf (0.4MB)Data_Alert.pdf (0.4MB)


Related at vwbg.org

The INTERHEART Study: New data on global risk

Cardiovascular disease (CVD) is estimated to be the leading cause of mortality and morbidity worldwide.

The new mandate for multiple risk reduction

Reducing the morbidity and mortality associated with cardiovascular (CV) disease is becoming as much a public health challenge as it is a research challenge.

Core Curriculum

Impact of vascular biology on cardiovascular disease, risk prevention, and treatment Section II: Blunting the atherosclerotic process: The case for aggressive lipid management

The VBWG Core Curriculum 2004: Impact of vascular biology on cardiovascular disease, risk prevention, and treatment.
More related